The Filing Desk

Beam Therapeutics vs Monte Rosa Therapeutics

Beam Therapeutics BEAM · Monte Rosa Therapeutics GLUE · Biotechnology

Beam Therapeutics reported revenue of $140 million in fiscal 2025, about the same as Monte Rosa Therapeutics' $124 million in fiscal 2025. Beam Therapeutics' revenue grew 120.0% in its latest year, and Monte Rosa Therapeutics' grew 63.5%. Beam Therapeutics had an operating margin of -274.6%, against -43.8% at Monte Rosa Therapeutics. Free cash flow was −$360 million at Beam Therapeutics and −$28 million at Monte Rosa Therapeutics.

Side by side

Beam TherapeuticsMonte Rosa Therapeutics
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$140M$124M
Revenue growth120.0%63.5%
Revenue growth a year, last 5 years——
Gross margin——
Operating margin−274.6%−43.8%
Net margin−57.2%−31.2%
Free cash flow−$360M−$28M
Free cash flow margin−257.6%−22.2%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count20.2%12.4%
Last close$22.83$9.37
P/E at the last close——
Insider trades, last 12 monthssold $18.5 million—
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Beam TherapeuticsMonte Rosa Therapeutics
Operating margin
Percent of revenue
Beam TherapeuticsMonte Rosa Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Beam TherapeuticsMonte Rosa Therapeutics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Beam Therapeutics and Monte Rosa Therapeutics pages.